Electronic supplementary material
The online version of this article (doi:10.1186/1472-6947-12-52) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
SKL conceived the study, participated in the design of the study, performed the statistical analysis, and drafted the manuscript. PRS participated in the design of the study, helped perform the statistical analysis, and helped with the interpretation of the data. SWV participated in the design of the study and helped critically review the manuscript. ROM critically reviewed the manuscript and helped with the interpretation of the data. PDM participated in the conception of the study and helped draft the manuscript. RJV contributed to the conception of the measure, supplied the data, and helped draft and revise the manuscript. All authors read and approved the final manuscript.
In order to explore the influence of anxiety on decision–making processes, valid anxiety measures are needed. We evaluated a prostate cancer screening (PCS) anxiety scale that measures anxiety related to the prostate–specific antigen (PSA) test, the digital rectal examination (DRE), and the decision to undergo PCS (PCS-D) using two samples in different settings.
We assessed four psychometric properties of the scale using baseline data from a randomized, controlled decision aid trial (n = 301, private clinic; n = 149, public).
The 3-factor measure had adequate internal consistency reliability, construct validity, and discriminant validity. Confirmatory factor analyses indicated that the 3–factor model did not have adequate fit. When subscales were considered separately, only the 6–item PCS-D anxiety measure had adequate fit and was invariant across clinics.
Our results support the use of a 6–item PCS-D anxiety measure with age-appropriate men in public and private settings. The development of unique anxiety items relating to the PSA test and DRE is still needed.